TipRanks
Advertisement
Advertisement

DE:E4NA Stock Latest News

Arovella Nears First Patient Dosing in Pivotal ALA-101 Cell Therapy Trial
Company AnnouncementsArovella Nears First Patient Dosing in Pivotal ALA-101 Cell Therapy Trial
2d ago
Arovella Deepens ESG Commitment Ahead of Australia’s Sustainability Rules
PremiumCompany Announcements
Arovella Deepens ESG Commitment Ahead of Australia’s Sustainability Rules
17d ago
Arovella Sets Hybrid 2026 AGM and Shifts to Default Digital Communications
PremiumCompany Announcements
Arovella Sets Hybrid 2026 AGM and Shifts to Default Digital Communications
25d ago
Arovella Details Governance Framework in 2026 Corporate Statement
PremiumCompany Announcements
Arovella Details Governance Framework in 2026 Corporate Statement
1M ago
Arovella lodges 2026 corporate governance statement and Appendix 4G
PremiumCompany Announcements
Arovella lodges 2026 corporate governance statement and Appendix 4G
1M ago
Arovella Narrows Annual Loss as Net Tangible Assets Per Share Fall
PremiumCompany AnnouncementsArovella Narrows Annual Loss as Net Tangible Assets Per Share Fall
1M ago
Arovella Issues 9.7 Million Unquoted Options Under Employee Incentive Scheme
Premium
Company Announcements
Arovella Issues 9.7 Million Unquoted Options Under Employee Incentive Scheme
2M ago
Arovella outlines strategy and ALA-101 trial timeline in investor webinar
Premium
Company Announcements
Arovella outlines strategy and ALA-101 trial timeline in investor webinar
2M ago
Arovella plans investor webinar ahead of first-in-human ALA-101 trial
PremiumCompany Announcements
Arovella plans investor webinar ahead of first-in-human ALA-101 trial
2M ago
Arovella Advances CAR-iNKT Programs as First Human Trial Nears
PremiumCompany Announcements
Arovella Advances CAR-iNKT Programs as First Human Trial Nears
2M ago
Arovella options lapse, easing potential shareholder dilution
PremiumCompany Announcements
Arovella options lapse, easing potential shareholder dilution
3M ago
Arovella Therapeutics Seeks ASX Quotation for Additional Shares
PremiumCompany Announcements
Arovella Therapeutics Seeks ASX Quotation for Additional Shares
3M ago
Arovella Director Increases Indirect Stake with On-Market Share Purchase
PremiumCompany AnnouncementsArovella Director Increases Indirect Stake with On-Market Share Purchase
4M ago
Arovella strengthens clinical team ahead of first ALA-101 human trial
Premium
Company Announcements
Arovella strengthens clinical team ahead of first ALA-101 human trial
4M ago
Arovella options lapse, trimming potential dilution in capital structure
Premium
Company Announcements
Arovella options lapse, trimming potential dilution in capital structure
4M ago
Arovella Therapeutics Options Lapse Clarifies Capital Structure
PremiumCompany Announcements
Arovella Therapeutics Options Lapse Clarifies Capital Structure
5M ago
Arovella Therapeutics Reports Director Andrew Nash’s Departure With No Security Interests
PremiumCompany Announcements
Arovella Therapeutics Reports Director Andrew Nash’s Departure With No Security Interests
5M ago
Arovella Highlights Solid-Tumour CAR-iNKT Advances at Global Cell Therapy Meeting
PremiumCompany Announcements
Arovella Highlights Solid-Tumour CAR-iNKT Advances at Global Cell Therapy Meeting
5M ago
Arovella names acting CEO as it heads into key Phase I trial
PremiumCompany Announcements
Arovella names acting CEO as it heads into key Phase I trial
5M ago
Arovella Overhauls Board as CEO Resigns, Launches Strategic Review
PremiumCompany AnnouncementsArovella Overhauls Board as CEO Resigns, Launches Strategic Review
5M ago
Arovella Appoints New Director With No Current Shareholdings
Premium
Company Announcements
Arovella Appoints New Director With No Current Shareholdings
5M ago
Arovella boosts board with four senior biotech and finance appointments
Premium
Company Announcements
Arovella boosts board with four senior biotech and finance appointments
5M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >